Twist Bioscience Corp — Director's Dealing 2021

Feb 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Twist Bioscience Corp (TWST)
CIK: 0001581280
Period of Report: 2021-02-03

Reporting Person: CRANDELL KEITH (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-03	Common Stock	A	486	—	Acquired	1898	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-03	Director Stock Option (right to buy)	$189.96	A	973	Acquired	2031-02-02	Common Stock (973)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	726834	Indirect
Common Stock	288104	Indirect
Common Stock	82692	Indirect

Footnotes

F1: Represents a restricted stock unit award (the "RSU Award") of which 100% vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date.

F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F3: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F4: Keith Crandell is a managing director of ARCH VII LLC and AVP GPLLC, and may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Mr. Crandell disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F5: 100% of the shares subject to the option will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Issuer's first annual meeting of stockholders following the date of grant, subject to the Reporting Person's continuous service through each vesting date.